Wegovy and beyond: Will weight-loss drugs change the way people look at obesity?
Earlier in July, pharmaceutical firm Novo Nordisk, which makes Wegovy, announced in a statement that the injectable drug is now available with prescription from any licensed physician at hospitals and clinics across Singapore.
The global hype around Wegovy, which is made for weight loss, stemmed from Ozempic, which was created as an anti-diabetic drug.
The latter garnered a lot of attention on social media a few years ago after its users, who weren't all diabetics, showed off their considerable weight loss.
What connects Wegovy and Ozempic – besides both being made by Novo Nordisk – is that they contain the active ingredient semaglutide.
Mimicking the natural hormone glucagon-like peptide-1, semaglutide regulates blood sugar levels, curbs the appetite and induces the sensation of fullness.
One of the differences? Wegovy has a higher maximum dosage of 2.4mg than Ozempic's 2mg.
While the benefits have been laid out, what should those considering Wegovy look out for?
To answer these questions on this episode of The Usual Place, I have:
Senior consultant endocrinologist Dr Sue-Anne Toh from Novi Health, a specialist medical clinic and health-tech company. She has more than 20 years of experience in internal medicine, diabetes, and metabolic health.
Her patient Farhan Hanis, a 26-year-old university student and a former plus-sized model. He started on Wegovy about two months ago.
General practitioner Dr Bosty Chan, who co-founded health telemedicine providers Sire and Dame, which offers weight management as part of a suite of services.
Tune in at 12pm SGT/HKT to watch the stream, and share your thoughts on our revamped YouTube channel.
Follow The Usual Place Podcast live at noon every Thursday and get notified for new episode drops:
Channel: https://str.sg/5nfm
Apple Podcasts: https://str.sg/9ijX
Spotify: https://str.sg/cd2P
YouTube: https://str.sg/theusualplacepodcast
Source: The Straits Times © SPH Media Limited. Permission required for reproduction
Discover how to enjoy other premium articles here
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
18 minutes ago
- Bloomberg
Hackers Steal Passwords From UK's NHS With Sneaky Malware Tool
Ambulances parked outside the emergency department at the National Health Service's Royal Liverpool University Hospital in Liverpool, UK.
Yahoo
39 minutes ago
- Yahoo
Novo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US Hurdles
Novo Nordisk A/S NVO reported second-quarter 2025 earnings of 97 cents per American Depositary Receipt (ADR), which beat the Zacks Consensus Estimate of 93 cents. The company had reported earnings of 65 cents per ADR in the year-ago quarter. Revenues of $11.68 billion increased 13% year over year in the Danish kroner (DKK) and 18% at the constant exchange rate (CER) in the reported quarter, driven by higher Diabetes and Obesity Care sales as GLP-1 product sales increased year over year, along with greater Rare disease sales. However, total revenues missed the Zacks Consensus Estimate of $11.79 billion. All growth rates mentioned below are on a year-over-year basis and at CER. NVO's Q2 Results in Detail Novo Nordisk operates under two segments: Diabetes and Obesity Care, and Rare disease. The Diabetes and Obesity Care segment reported sales of DKK 71.94 billion in the quarter under review, representing a 17% increase. In Diabetes Care, fast-acting insulin Fiasp's revenues were down 5%. NovoRapid revenues increased 26% and Human insulin revenues decreased 26%. Premix insulin (Ryzodeg and NovoMix) revenues rose 11%. Sales of long-acting insulins (Tresiba, Xultophy, Levemir and Awiqli) decreased 2% in the second quarter. Ozempic, which has witnessed a strong launch and solid uptake so far, recorded sales of DKK 31.8 billion for the quarter, up 15%. Rybelsus recorded sales of DKK 5.65 billion for the quarter, down 1%. Victoza sales declined 57% during the reported quarter. Obesity Care (Saxenda and Wegovy) sales were up 53% to DKK 20.37 billion. Wegovy's sales growth rate continues to slow, with second-quarter sales reaching DKK 19.53 billion, up 75%, as growth was impacted by the availability of illegal compounded versions in Novo Nordisk's largest obesity market, the United States. Year to date, shares of NVO have plunged 45.1% compared with the industry's 3.7% decline. Image Source: Zacks Investment Research Sales in the Rare disease segment were up 28% to DKK 4.92 billion in the second quarter of 2025. Sales of rare blood disorder products were DKK 3.1 billion, up 13%. Sales of hemophilia A products declined 1%. Hemophilia B products' sales declined 4%. Sales of NovoSeven increased 16% to DKK 2 billion. Sales of Novo Nordisk's rare endocrine disorder products jumped 100% to DKK 1.42 billion. Sales and distribution costs climbed 19% in the reported quarter to DKK 17.53 billion. This increase was due to promotional activities related to Wegovy in the United States. In International Operations, costs related to the Wegovy launch and promotional activities for Ozempic contributed to the increase. Research and development (R&D) costs were down 26% to DKK 11.69 billion. The decrease was primarily attributed to a DKK 5.7 billion impairment loss related to ocedurenone and other intangible asset impairments recorded in the year-ago period, partially offset by increased investment in late-stage clinical studies and research activities, mainly within the Obesity Care segment. NVO Cuts 2025 Outlook Novo Nordisk already announced slashing its 2025 guidance for both sales and operating profit growth last week, following which its shares tumbled. It now expects sales to increase 8-14%, down from the previous 13-21% range, and operating profit to grow 10-16% compared to the earlier 16-24% estimate, all at CER. The revision reflects weaker-than-anticipated momentum for key drugs Wegovy and Ozempic, particularly in the U.S. market, where Wegovy is struggling with the continued use of unregulated, compounded GLP-1 alternatives. Despite the FDA ending its compounding grace period in May 2025, illegal semaglutide sales persist under the guise of 'personalized medicine,' prompting NVO to take legal and regulatory action. The company also cited slower-than-expected Wegovy uptake across both insured and cash-pay channels, limited by modest market expansion and growing competition. While efforts through NovoCare and telehealth have spurred some growth, overall adoption remains below expectations. Ozempic is similarly seeing increased competitive pressure in the U.S. diabetes market. International Wegovy rollouts are underway, but demand in certain regions has been slower than projected. On the profit front, Novo Nordisk's lower operating profit outlook is tied to reduced sales expectations, though partially cushioned by cost controls. The updated forecast also reflects a mid-single-digit drag from its acquisition of three Catalent manufacturing sites. Novo Nordisk's global diabetes value market share declined 1.4% over the past year to 32.6% due to increased competition from arch-rival Eli Lilly LLY, which markets its tirzepatide medicines as Mounjaro for diabetes and Zepbound for obesity. Despite being on the market for less than three years, Lilly's Mounjaro and Zepbound have witnessed strong sales driven by rapid demand. LLY is scheduled to report second-quarter results on Aug. 7, before the opening bell. However, Novo Nordisk remains focused on reinforcing its leadership in diabetes care, targeting a global market share of over one-third by 2025. Our Take Novo Nordisk reported weaker-than-expected second-quarter revenues. Despite year-over-year increases in the sales of its Diabetes and Obesity Care and Rare disease products, the company's total revenues fell short of expectations, primarily due to a slowdown in sales of its flagship GLP-1 obesity drug, Wegovy, amid increased availability of compounded alternatives. Novo Nordisk is eyeing a comeback on the back of expanded indications of its semaglutide drugs as well as good pipeline progress with several other new candidates for diabetes and obesity. These are part of the company's efforts to tackle increasing competition from Eli Lilly, especially in the U.S. market. The FDA is currently reviewing Novo Nordisk's application for a 25 mg oral Wegovy for obesity, with a decision expected by year-end. A positive outcome should boost Novo Nordisk's revenues as no other oral GLP-1 treatments for obesity are currently on the market. Oral pills, being more convenient than injectables, tend to boost patient adherence. Another filing seeking approval for Wegovy to treat metabolic dysfunction-associated steatohepatitis is also currently under FDA review. NVO has also filed Rybelsus for cardiac event prevention in diabetes. Label expansion is also being sought for Ozempic in treating peripheral artery disease in the United States and the EU. Beyond metabolic diseases, NVO is also building out its rare disease segment, with late-stage progress on Mim8 for hemophilia A and recent FDA approval of a broader label for its Alhemo injection for hemophilia A or B with/without inhibitors, further strengthening its position in the hemophilia space. Novo Nordisk remains optimistic about an increase in volume of Wegovy sales in the second half of 2025 through initiatives like NovoCare Pharmacy and CVS' exclusive formulary coverage, effective 1 July 2025, where the drug is now the only GLP-1 medicine covered for obesity. Novo Nordisk A/S Price, Consensus and EPS Surprise Novo Nordisk A/S price-consensus-eps-surprise-chart | Novo Nordisk A/S Quote NVO's Zacks Rank & Stocks to Consider Novo Nordisk currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the biotech sector are Arvinas ARVN and Immunocore IMCR, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here. In the past 60 days, estimates for Arvinas' 2025 loss per share have narrowed from $1.51 to $1.50. Loss per share estimates for 2026 have narrowed from $3.08 to $2.98 during the same period. ARVN stock has plunged 60.3% year to date. Arvinas' earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 82.09%. In the past 60 days, estimates for Immunocore's 2025 loss per share have narrowed from 86 cents to 68 cents. Loss per share estimates for 2026 have narrowed from $1.34 to $1.10 during the same period. IMCR stock has increased 10.2% year to date. Immunocore's earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 76.18%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Arvinas, Inc. (ARVN) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Forbes
an hour ago
- Forbes
USAID And PEPFAR Cuts Could Lead To Massive Loss Of Life Overseas
A Lancet paper published in July evaluates data to illustrate the importance of roughly two decades of American humanitarian aid offered through the United States Agency for International Development and the President's Emergency Plan for AIDS Relief. The piece subsequently projects what the future could look like in light of the steep cuts imposed by President Trump to USAID and PEPFAR. Authors estimate that USAID-funded programs have helped prevent more than 91 million deaths globally in the past 20 years, including 30 million fatalities among children. Projections suggest that ongoing deep funding cuts—combined with the dismantling of the agency—could result in more than 14 million additional deaths by 2030. On inauguration day, President Trump ordered a sweeping 90-day spending freeze on virtually all U.S. foreign aid, including many forms of health and food assistance. An independent agency, USAID, was largely gutted. The USAID undertakes a wide range of activities, which include among other things food aid and distribution (often in conflict zones), clean water provision, maternal and infant health support, mass administration of rehydration salts for children suffering from diarrhea, malaria prevention and treatments and polio vaccinations in countries where the disease is still endemic. The agency was established under President John F. Kennedy in the early 1960s to administer humanitarian aid programs around the world. Congress appropriates funds for USAID's operations. The agency employed roughly 10,000 people, two-thirds of whom worked overseas. In fiscal year 2024, the agency received more than $44 billion in federal funding. Most of that money was spent in Asia, sub-Saharan Africa and Europe (primarily on humanitarian efforts in Ukraine). While a considerable sum, it merely accounts for 0.4% of the entire federal budget. The Trump administration has slashed 86% of USAID funding. Only a small fraction of aid programs remains in place. The employee head count is now under 500. As carried out by successive administrations since Bush, including the first Trump administration, PEPFAR represented the largest commitment in history by any nation to address a single disease, HIV/AIDS. But gradually the second Trump administration is unraveling this initiative, too. KFF reported that while PEPFAR received a limited waiver on Feb. 1, allowing it to continue certain 'life-saving HIV services,' the waiver doesn't include essential pre-exposure prophylaxis for anyone other than pregnant and breastfeeding women. The State Department has sought $2.9 billion in funding to continue HIV-AIDS programs in the next fiscal year—considerably lower than PEPFAR's current budget of $4.1 billion. Moreover, USAID was the main agency working on behalf of PEPFAR. Without USAID and its staff, PEPFAR's implementation capacity has been seriously affected. Going forward, the Trump administration intends to transform PEPFAR from an aid program to one that is aligned with its 'America First' priorities. The plan, as described by the New York Times, outlines the administration's intentions to 'transition' countries off of PEPFAR, in some cases within two years. The program would in essence no longer be involved in aid and saving lives overseas. Rather, it would focus on detecting outbreaks that could threaten the U.S. and at the same time create new markets for American drugs and technologies. On the ground, journalists are painting a grim picture of the implications of the drastic curtailment in U.S. aid. A story in America Magazine, for example, describes in detail the local impact in Eswatini, a country in Southern Africa, of the gutting of USAID and reductions in PEPFAR. Cuts have severely limited access to HIV treatments and testing in clinics. During the height of the HIV/AIDS pandemic, the population of Eswatini plummeted, and life expectancy dropped from 61 in 1988 to 44 by 2003. It reverted to 61 in 2023, thanks in large part to USAID and PEPFAR. But now the gains in health outcomes are in jeopardy. The ramifications of a greatly diminished U.S. presence in health aid, international development and disaster assistance could be profound, specifically around the global humanitarian programs which rely on USAID. In terms of international assistance, the U.S. was by far the world's largest donor. The U.S. spent $68 billion on international aid in 2023. And the Trump administration's actions are also affecting what is termed the President's Malaria Initiative, an organization also founded by former President Bush. Through the work of this entity, the U.S. had become the global leader in donating to anti-malaria programs and research. According to the New York Times, one of Trump's executive orders has led to two-thirds of the staff being let go from the Malaria Initiative. And by pulling out of the World Health Organization, Trump further diminishes the critical role the U.S. plays in combating neglected tropical diseases, such as leishmaniasis, river blindness, Dengue fever and trachoma. These preventable and mostly treatable infectious diseases affect millions of people in tropical regions of the world, causing severe health problems, including anemia, blindness, chronic pain, infertility and bodily disfigurement. Historically, despite the large burden imposed by neglected tropical diseases on many people, they've received a relatively small portion of resources for drug development and treatment distribution. U.S. aid agencies had been filling some of the void. Until now.
